{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:07:34Z","timestamp":1784675254929,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T00:00:00Z","timestamp":1363046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00280-013-2129-6","type":"journal-article","created":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T02:42:27Z","timestamp":1362969747000},"page":"1297-1307","source":"Crossref","is-referenced-by-count":35,"title":["Benchmarking effects of mTOR, PI3K, and dual PI3K\/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib"],"prefix":"10.1007","volume":"71","author":[{"given":"Maria","family":"Serova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemila\u00ef","family":"Tijeras-Raballand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Riveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khemaies","family":"Slimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"2129_CR1","unstructured":"International Agency for Research on Cancer. Globocan 2008 Fast Stats: hepatocellular carcinoma: Worldwide Incidence and Mortality. International Agency for Research on Cancer Web Site. Available at http:\/\/globocan.iarc.fr\/"},{"key":"2129_CR2","unstructured":"International Agency for Research on Cancer. Globocan 2008 Fast Stats: Renal Cell Carcinoma: Worldwide Incidence and Mortality. International Agency for Research on Cancer Web Site. Available at http:\/\/globocan.iarc.fr\/bar_pop.asp?selection=221900&title=World&sex=0&statistic=0&window=1&grid=1&info=1&color1=4&color1e=&color2=5&color2e=&orientation=1&submit=%A0Execute%A0"},{"key":"2129_CR3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators Study Group","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"2129_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"2129_CR5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280\u20131289","journal-title":"J Clin Oncol"},{"key":"2129_CR6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312\u20133318","journal-title":"J Clin Oncol"},{"key":"2129_CR7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278\u20132287","journal-title":"J Clin Oncol"},{"key":"2129_CR8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671\u2013688","journal-title":"Nat Rev Drug Discov"},{"key":"2129_CR9","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.17.11.1619","volume":"17","author":"S Faivre","year":"2008","unstructured":"Faivre S, Raymond E (2008) Mechanism of action of rapalogues: the antiangiogenic hypothesis. Exp Opin Invest Drugs 17:1619\u20131621","journal-title":"Exp Opin Invest Drugs"},{"key":"2129_CR10","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108:3749\u20133754","journal-title":"Proc Natl Acad Sci USA"},{"key":"2129_CR11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2129_CR12","doi-asserted-by":"crossref","first-page":"v137","DOI":"10.1093\/annonc\/mdq206","volume":"21","author":"B Escudier","year":"2010","unstructured":"Escudier B, Kataja V (2010) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v137\u2013v139","journal-title":"Ann Oncol"},{"key":"2129_CR13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","volume":"58","author":"B Ljungberg","year":"2010","unstructured":"Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398\u2013406","journal-title":"Eur Urol"},{"key":"2129_CR14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","volume":"45","author":"TM Reijke de","year":"2009","unstructured":"de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45:765\u2013773","journal-title":"Eur J Cancer"},{"key":"2129_CR15","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122 Kidney Cancer (Version 2.2012). 2012. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"2129_CR16","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256\u20134265","journal-title":"Cancer"},{"key":"2129_CR17","unstructured":"U.S. National Institutes of Health. ClinicalTrials.Gov Web Site. Available at http:\/\/www.clinicaltrials.gov\/ct2\/home . Accessed 23 July 2012"},{"key":"2129_CR18","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.2174\/138161212800626210","volume":"18","author":"A Fasolo","year":"2012","unstructured":"Fasolo A, Sessa C (2012) Targeting mTOR pathways in human malignancies. Curr Pharm Des 18:2766\u20132777","journal-title":"Curr Pharm Des"},{"key":"2129_CR19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11523-011-0177-6","volume":"6","author":"C Delbaldo","year":"2011","unstructured":"Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S (2011) Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol 6:119\u2013124","journal-title":"Target Oncol"},{"key":"2129_CR20","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci USA 98:10314\u201310319","journal-title":"Proc Natl Acad Sci USA"},{"key":"2129_CR21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/me.2009-0328","volume":"24","author":"A Veilleux","year":"2010","unstructured":"Veilleux A, Houde VP, Bellmann K, Marette A (2010) Chronic inhibition of the mTORC1\/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 24:766\u2013778","journal-title":"Mol Endocrinol"},{"key":"2129_CR22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1023\/B:APPT.0000045781.46314.e2","volume":"9","author":"D Aguirre","year":"2004","unstructured":"Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, Benard J, Saulnier P, Hopkins-Donaldson S, Zangemeister-Wittke U, Kroemer G, Raymond E (2004) Bcl-2 and CCND1\/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9:797\u2013805","journal-title":"Apoptosis"},{"key":"2129_CR23","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5\u00a0days every 2\u00a0weeks to patients with advanced cancer. Clin Cancer Res 12:5755\u20135763","journal-title":"Clin Cancer Res"},{"key":"2129_CR24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588\u20131595","journal-title":"J Clin Oncol"},{"key":"2129_CR25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","volume":"10","author":"E Vilar","year":"2011","unstructured":"Vilar E, Perez-Garcia J, Tabernero J (2011) Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10:395\u2013403","journal-title":"Mol Cancer Ther"},{"key":"2129_CR26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70:288\u2013298","journal-title":"Cancer Res"},{"key":"2129_CR27","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","volume":"16","author":"DC Cho","year":"2010","unstructured":"Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW (2010) The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16:3628\u20133638","journal-title":"Clin Cancer Res"},{"key":"2129_CR28","doi-asserted-by":"crossref","unstructured":"Dolly S, Wagner AJ, Bendell JC, Yan Y, Ware JA, Mazina KE, Holden SN, Derynck MK, De Bono JS, Burris HA III (2010) A first-in-human, phase l study to evaluate the dual PI3K\/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin\u2019s lymphoma [abstract]. J Clin Oncol 28(May 20 suppl):3079","DOI":"10.1200\/jco.2010.28.15_suppl.3079"},{"key":"2129_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317\u2013328","journal-title":"Mol Cancer Ther"},{"key":"2129_CR30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","volume":"10","author":"AC Piguet","year":"2011","unstructured":"Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V, Dufour JF (2011) Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10:1007\u20131017","journal-title":"Mol Cancer Ther"},{"key":"2129_CR31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","volume":"7","author":"PH Patel","year":"2009","unstructured":"Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24\u201327","journal-title":"Clin Genitourin Cancer"},{"key":"2129_CR32","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.26429","volume":"118","author":"AM Molina","year":"2012","unstructured":"Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ (2012) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118:1868\u20131876","journal-title":"Cancer"},{"key":"2129_CR33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1476-4598-10-90","volume":"10","author":"D Roulin","year":"2011","unstructured":"Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10:90","journal-title":"Mol Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2129-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2129-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T15:46:21Z","timestamp":1562773581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2129-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,12]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2129-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,12]]}}}